文献类型：期刊文献

中文题名：国人NLRP3和GSTP1基因多态性与慢性阻塞性肺疾病易感性研究进展

英文题名：Research progress on NLRP3 and GSTP1 gene polymorphisms and chronic obstructive pulmonary disease susceptibility in Chinese

作者：张春艳[1];王云超[2];王啟秀[1];余静[1];王新华[1]

第一作者：张春艳

机构：[1]甘肃中医药大学公共卫生学院,兰州730000;[2]甘肃中医药大学基础医学院,兰州730000

第一机构：甘肃中医药大学公共卫生学院

年份：2022

卷号：42

期号：14

起止页码：1103

中文期刊名：国际呼吸杂志

外文期刊名：International Journal of Respiration

收录：CSTPCD

基金：国家重点研发计划(2017YFC0907202);兰州市科技计划项目(2022-ZD-136)。

语种：中文

中文关键词：肺疾病,慢性阻塞性;谷胱甘肽S转移酶P1;核苷酸结合寡聚化结构域样受体蛋3;基因多态性

外文关键词：Pulmonary disease,chronic obstructive;Glutathione S transferase P1;Nucleotide-binding oligomerization domain-like receptor protein 3;Gene polymorphism

摘要：慢性阻塞性肺疾病(COPD)是以气流受限为特征的肺部疾病,其发病率和病死率较高、致病因素较复杂,主要是由遗传因素和环境因素共同作用所致。其发病机制主要以炎症机制、蛋白酶-抗蛋白酶失衡以及氧化-抗氧化失衡3种假说为主。GSTP1作为抗氧化酶在肺脏中具有重要的抗氧化作用,但由于GSTP1基因具有多态性,使得GSTP1的抗氧化能力显著降低,导致体内氧化-抗氧化失衡,从而认为GSTP1基因多态性是COPD的危险因素之一;NLRP3作为炎性小体构成组分被证实参与COPD的炎症反应,而其基因多态性可使NLRP3结构发生改变从而可能影响COPD的发生。现对GSTP1和NLRP3基因多态性与COPD的相关性作一综述,以期在此基础上通过相关实验佐证为COPD的干预及靶向治疗提供新途径和新思路。
Chronic obstructive pulmonary disease(COPD)is a pulmonary disease characterized by airflow restriction,with high morbidity and mortality and complex pathogenic factors,mainly the combined action of genetic factors and environmental factors.The pathogenesis is mainly based on three hypotheses:inflammatory mechanism,protease-antiprotease imbalance,and oxidation-antioxidation imbalance.GSTP1,as an antioxidant enzyme,plays an important role in lung oxidation.However,due to the polymorphism of GSTP1 gene,the antioxidant capacity of GSTP1 is significantly reduced,leading to the imbalance between oxidation and antioxidant in vivo.Therefore,GSTP1 gene polymorphism is considered one of the risk factors of COPD.NLRP3,as an inflammasome component,is confirmed to be involved in the inflammatory response of COPD,and its gene polymorphism may alter the structure of NLRP3,which may affect the occurrence of COPD.This paper reviews the correlation of GSTP1 and NLRP3 gene polymorphism and COPD,so as to,through relevant experimental evidence,provide new approaches and noval ideas for COPD intervention and targeted therapy.